These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15809523)

  • 1. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
    Stemmler J; Mair W; Stauch M; Papke J; Deutsch G; Abenhardt W; Dorn B; Kentenich C; Malekmohammadi M; Jackisch C; Leinung S; Brudler O; Vehling-Kaiser U; Stamp J; Heinemann V
    Oncology; 2005; 68(1):71-8. PubMed ID: 15809523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
    Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
    J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
    Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
    J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
    Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
    Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
    Hosonaga M; Ito Y; Tokudome N; Takahashi S; Iwase T; Hatake K
    Breast Cancer; 2012 Oct; 19(4):329-34. PubMed ID: 21863309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.
    Stemmler HJ; Harbeck N; Gröll de Rivera I; Vehling Kaiser U; Rauthe G; Abenhardt W; Artmann A; Sommer H; Meerpohl HG; Kiechle M; Heinemann V
    Oncology; 2010; 79(3-4):197-203. PubMed ID: 21358207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
    Im SA; Kim SB; Lee MH; Im YH; Lee KH; Song HS; Lee MA; Lee J; Lee NS; Ham HS; Kim TY; Park YH; Lee KE; Kim KW; Seo JH; Lee SN; Hong YS; Bang YJ; Kim WK; Park HS
    Oncol Rep; 2005 Aug; 14(2):481-7. PubMed ID: 16012734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protracted administration of weekly docetaxel in metastatic breast cancer.
    Kuroi K; Bando H; Saji S; Toi M
    Oncol Rep; 2003; 10(5):1479-84. PubMed ID: 12883727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predicting docetaxel-related toxicity: experience at a single institution.
    Massacesi C; Marcucci F; Rocchi MB; Mazzanti P; Pilone A; Bonsignori M
    J Chemother; 2004 Feb; 16(1):86-93. PubMed ID: 15078005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.
    Beuselinck B; Wildiers H; Wynendaele W; Dirix L; Kains JP; Paridaens R
    Crit Rev Oncol Hematol; 2010 Jul; 75(1):70-7. PubMed ID: 19651523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
    Schuette W; Nagel S; Blankenburg T; Lautenschlaeger C; Hans K; Schmidt EW; Dittrich I; Schweisfurth H; von Weikersthal LF; Raghavachar A; Reissig A; Serke M
    J Clin Oncol; 2005 Nov; 23(33):8389-95. PubMed ID: 16293869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.
    Trent JC; Valero V; Booser DJ; Esparza-Guerra LT; Ibrahim N; Rahman Z; Vernillet L; Patel S; David CL; Murray JL; Cristofanilli M; Hortobagyi GN
    Clin Cancer Res; 2003 Jul; 9(7):2426-34. PubMed ID: 12855614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
    Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
    Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
    Lee JL; Ryu MH; Chang HM; Kim TW; Yook JH; Oh ST; Kim BS; Kim M; Chun YJ; Lee JS; Kang YK
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):631-7. PubMed ID: 17520252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
    Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
    Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.
    Estévez LG; Cuevas JM; Antón A; Florián J; López-Vega JM; Velasco A; Lobo F; Herrero A; Fortes J
    Clin Cancer Res; 2003 Feb; 9(2):686-92. PubMed ID: 12576436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
    Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM
    J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.